Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
28
Aug |
Wound Management Technologies Expands Distribution Foot Print In Florida With The Addition Of Central Medical SystemsCategory: Diabetes | Leave a Comment |
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced that its subsidiary Wound Care Innovations, LLC has further expanded its rapidly growing coverage of the Florida wound care market with the addition of Central Medical Systems to its already extensive list of distributors and suppliers…
|
25
Aug |
Echo Therapeutics Announces Successful Completion Of Clinical Trial For Prelude™ SkinPrep System And 4% Lidocaine CreamCategory: Diabetes | Leave a Comment |
Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, announced the completion of a clinical study of Prelude…
|
17
Aug |
Key Step On Road To An Artificial PancreasCategory: Diabetes | Leave a Comment |
JDRF has announced another important step on the road to the development of an artificial pancreas - an automated system to better manage the blood sugar of people with type 1 diabetes - with the establishment of a research program to speed the development of faster-acting insulin…
|
10
Aug |
New Device To Monitor Glucose Levels Without Finger PricksCategory: Diabetes | Leave a Comment |
People with type 1 diabetes must keep a careful eye on their blood glucose levels: Too much sugar can damage organs, while too little deprives the body of necessary fuel. Most patients must prick their fingers several times a day to draw blood for testing…
|
5
Aug |
Decision To Withdraw Diabetes Drug Could Add 9 Million Pounds To NHS Drugs Bill In The UKCategory: Diabetes | Leave a Comment |
Drug company Novo Nordisk’s decision to pull its Mixtard 30 insulin drug from the UK could add 9 million pounds to the NHS drugs bill in England alone, says an editorial in the Drug and Therapeutics Bulletin (DTB)…
|
1
Aug |
Wireless Glucose Sensor In Development, UKCategory: Diabetes | Leave a Comment |
Researchers in the UK have developed an implantable sensor that measures blood glucose levels continuously and transmits the information wirelessly. The sensor, however, has so far only been tested in pigs. The small, round device is being touted as having the potential to overhaul the way people with diabetes control their condition…
|
1
Aug |
GlucaGen Injections - Diabetes UKCategory: Diabetes | Leave a Comment |
European stocks of GlucaGen injections have been limited due to a manufacturing process problem that has now been resolved. The shortage is unlikely to affect people with diabetes directly. There are no quality implications for GlucaGen already in the supply chain, either in the UK or any other market…
|
29
Jul |
Implanted Wireless Glucose Sensor That Could Transform Management Of Diabetes Passes Crucial TestCategory: Diabetes | Leave a Comment |
American bioengineers have demonstrated that an implanted glucose sensor with potential to transform the management of diabetes has passed a crucial test: the device they developed worked continuously in animals for over a year, without showing signs of “tissue encapsulation” seen in trials with other similar devices…
|
27
Jul |
Calibra Gains FDA Clearance To Market Finesse™ Insulin Patch-Pen For Three-Day Use With Novolog®Category: Diabetes | Leave a Comment |
Calibra Medical announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk’s Novolog® rapid acting insulin…
|
15
Jul |
New Treatment For Crippling Diabetic Charcot FootCategory: Diabetes | Leave a Comment |
The alarming increase of morbidly obese diabetics is causing more new cases of a debilitating foot deformity called Charcot foot. Charcot foot can make walking difficult or impossible, and in severe cases can require amputation…